Table of Content


Executive Summary



Chapter 1 – Introduction



Chapter 2 – Trends in immunology dealmaking



2.1. Introduction

2.2. Immunology partnering over the years

2.3. Immunology partnering by deal type

2.4. Immunology partnering by industry sector

2.5. Immunology partnering by stage of development

2.6. Immunology partnering by technology type

2.7. Immunology partnering by therapeutic indication



Chapter 3 – Financial deal terms for immunology partnering



3.1. Introduction

3.2. Disclosed financials terms for immunology partnering

3.3. Immunology partnering headline values

3.4. Immunology deal upfront payments

3.5. Immunology deal milestone payments

3.6. Immunology royalty rates



Chapter 4 – Leading immunology deals and dealmakers



4.1. Introduction

4.2. Most active in immunology partnering

4.3. List of most active dealmakers in immunology

4.4. Top immunology deals by value



Chapter 5 – Immunology contract document directory



5.1. Introduction

5.2. Immunology partnering deals where contract document available



Chapter 6 – Immunology dealmaking by therapeutic target



6.1. Introduction

6.2. Deals by immunology therapeutic target



Deal directory



Deal directory – Immunology deals by company A-Z 2016 to 2023

Deal directory – Immunology deals by technology type 2016 to 2023



Deal type definitions



About Wildwood Ventures



Current Partnering

Current Agreements

Recent report titles from CurrentPartnering



Table of figures



Figure 1: Immunology partnering since 2016

Figure 2: Immunology partnering by deal type since 2016

Figure 3: Immunology partnering by industry sector since 2016

Figure 4: Immunology partnering by stage of development since 2016

Figure 5: Immunology partnering by technology type since 2016

Figure 6: Immunology partnering by indication since 2016

Figure 7: Immunology deals with a headline value

Figure 8: Immunology deals with upfront payment values

Figure 9: Immunology deals with milestone payment

Figure 10: Immunology deals with royalty rates

Figure 11: Active immunology dealmaking activity since 2016

Figure 12: Top immunology deals by value since 2016